Translational Development Acquisition Corp. (TDAC) Financial Statements
Industry: Blank Checks
In fiscal 2025, Translational Development Acquisition reported revenue of $0. Net income was $6.4M, or $0.29 per diluted share. Operating activities generated -$608,387 of cash. At fiscal year end, Translational Development Acquisition held $181.7M in total assets against $6.6M in total liabilities, including $29,787 of cash and equivalents.
Open the full interactive Translational Development Acquisition financials → Quarterly statements, key ratios, valuation history and price charts.
Translational Development Acquisition Key Stats
| Share Price | $10.83 |
|---|---|
| Market Cap | $182.5M |
| P/E Ratio | 37.3 |
| 52-Week Range | $10.35 – $10.90 |
| Shares Outstanding | 16.9 million (basic, 2026 Q2) |
Translational Development Acquisition Income Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Revenue | $0 | $0 |
| Cost of Goods Sold | $0 | — |
| Gross Profit | $0 | — |
| Operating Income | -$196,358 | -$944,538 |
| Pre-Tax Income | -$71,012 | $6.4M |
| Income Tax | $0 | — |
| Net Income | -$71,012 | $6.4M |
| Diluted EPS | -$0.01 | $0.29 |
Translational Development Acquisition Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | $1.7M | $1.6M | $1.3M | $946,982 |
| Diluted EPS | $0.08 | $0.09 | $0.06 | $0.04 |
Translational Development Acquisition Balance Sheet
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash & Equivalents | $438,174 | $29,787 |
| Current Assets | $650,233 | $39,465 |
| Total Assets | $175.0M | $181.7M |
| Current Liabilities | $210,303 | $544,073 |
| Total Liabilities | $6.2M | $6.6M |
| Shareholders' Equity | -$5.6M | -$6.5M |
Translational Development Acquisition Cash Flow Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash From Operations | -$851,446 | -$608,387 |
| Cash From Investing | -$174.2M | — |
| Cash From Financing | $175.5M | $200,000 |
Figures from Translational Development Acquisition's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Translational Development Acquisition financials page for every line item.
Translational Development Acquisition Company Profile
| Ticker | TDAC |
|---|---|
| Exchange | Nasdaq |
| Industry | Blank Checks |
| Headquarters | New York, New York |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company, emerging growth company |
| SEC CIK | 0001926599 |
Frequently Asked Questions
What was Translational Development Acquisition's revenue in fiscal 2025?
Translational Development Acquisition (TDAC) reported revenue of $0 for fiscal 2025.
What was Translational Development Acquisition's net income in fiscal 2025?
Translational Development Acquisition reported net income of $6.4M for fiscal 2025.
What was Translational Development Acquisition's earnings per share (EPS) in fiscal 2025?
Translational Development Acquisition's diluted EPS was $0.29 for fiscal 2025 (adjusted for any later stock splits).
What was Translational Development Acquisition's revenue last quarter?
In its most recent reported quarter (2026 Q2), Translational Development Acquisition reported revenue of $0.
How many shares of Translational Development Acquisition are outstanding?
Translational Development Acquisition reported a weighted average of 16.9 million basic shares outstanding in 2026 Q2.
What is Translational Development Acquisition's market cap?
Based on its latest closing price, Translational Development Acquisition (TDAC) has a market capitalization of about $182.5M.
When does Translational Development Acquisition's fiscal year end?
Translational Development Acquisition's fiscal year end, as registered with the SEC, is December 31.
Where is Translational Development Acquisition headquartered?
Translational Development Acquisition lists its business address in New York, New York in its SEC filings.